Magnesium membrane versus cortical lamina for vestibular socket therapy during immediate implant placement in upper front tooth sockets
Vestibular Socket Therapy Using Magnesium Membrane Versus Cortical Lamina for Immediate Implant Placement in Type II Extraction Sockets: A Randomized Controlled Clinical Trial
This trial tests whether a bioresorbable magnesium membrane helps bone and soft-tissue healing better than a traditional cortical lamina for people receiving immediate implants in Type II maxillary anterior extraction sockets.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Sex | All |
| Sponsor | Misr University for Science and Technology Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Giza) |
| Trial ID | NCT07526272 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial compares two barrier materials—a rigid cortical lamina and a bioresorbable magnesium membrane—used with Vestibular Socket Therapy (VST) for immediate implant placement in Type II extraction sockets. VST is a minimally invasive approach that uses a small incision and a subperiosteal tunnel to place a bone shield and graft without raising a full flap. Twenty-four patients are randomized to one of the two materials and followed from baseline to six months with clinical and radiographic assessments of bone fill, implant stability, and soft-tissue outcomes. The trial aims to determine whether the magnesium membrane provides comparable mechanical support and enhanced biological healing compared with the established cortical lamina.
Who should consider this trial
Good fit: Adults needing immediate implant placement in maxillary anterior teeth with Type II (deficient labial height) extraction sockets, with at least 3.0 mm of basal bone, who are non-smokers and not pregnant or recently treated with chemo/radiotherapy, are the intended participants.
Not a fit: Current smokers, pregnant or lactating individuals, patients with debilitating systemic disease or recent chemotherapy/radiotherapy, or those without sufficient basal bone are unlikely to qualify or benefit from this protocol.
Why it matters
Potential benefit: If successful, the magnesium membrane could provide a resorbable, mechanically supportive barrier that speeds or improves bone regeneration and reduces the need for additional grafting or membrane removal.
How similar studies have performed: Cortical lamina is an established barrier with documented use in socket reconstruction, while magnesium membranes are an emerging, promising technology with encouraging preclinical and early clinical reports but limited long-term human data in immediate implant VST.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Single or multiple teeth with hopeless prognosis in maxillary anterior teeth with either type I or type II extraction sockets. * Deficient labial bone plate in width (type I) and height (type II) sockets. * Minimal of 3.0 mm basal bone present for immediate implant placement to achieve optimum primary stability. Exclusion Criteria: * Current smokers. * Patients with debilitating systemic disease. * Patients who have undergone any sort of radiotherapy and chemotherapy in past 2 years. * Pregnant and Lactating females.
Where this trial is running
Giza
- Misr University for Science and Technology — Giza, Egypt (Recruiting)
Study contacts
- Study coordinator: Mohamed A Alfeky
- Email: mohamed.alfeky@must.edu.eg
- Phone: +201060104208
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.